On Tuesday, Berkshire Hathaway Inc. (NYSE:BRK.B)’s shares declined -0.08% to $141.42.
H.J. Heinz Co said that Warren Buffett’s Berkshire Hathaway Inc has become its majority shareholder by exercising a warrant ahead of the ketchup maker’s planned merger with Kraft Foods Group Inc .
In a regulatory filing, Heinz said Berkshire exercised a warrant to acquire about 46.2 million shares for nearly $462,000 this week.
Heinz said the shares represent about 5.4 percent of its outstanding common stock, and that their issuance gives Berkshire a 52.5 percent overall stake.
The warrant was issued in connection with Heinz’s $23 billion acquisition by Berkshire and Brazilian private equity firm 3G Capital in 2013.
Shareholders of Kraft are planned to vote on July 1 on the Heinz merger, which would create one of the world’s largest food and beverage companies.
Heinz owners would get a 51 percent stake in the combined company, which would be known as Kraft Heinz Co.
Berkshire would own about 27 percent of the combined company, but 3G would oversee day-to-day operations.
Kraft brands comprise its namesake cheese, Oscar Mayer cold cuts and Maxwell House coffee. The company has said it anticipates to close the merger a few business days after shareholder approval.
Berkshire Hathaway, Inc. is a publicly owned investment manager. Through its auxiliaries, the firm primarily engages in the insurance and reinsurance of property and casualty risks business. Berkshire Hathaway was founded in 1889 and is based in Omaha, Nebraska.
Berkshire Hathaway, Inc. is a publicly owned investment manager. Through its subsidiaries, the firm primarily engages in the insurance and reinsurance of property and casualty risks business. Berkshire Hathaway was founded in 1889 and is based in Omaha, Nebraska.
Opexa Therapeutics Inc (NASDAQ:OPXA)’s shares dropped -9.73% to $0.485.
Opexa Therapeutics, Inc. (OPXA), a biopharmaceutical company developing personalized immunotherapies for autoimmune disorders counting multiple sclerosis (MS) and neuromyelitis optica (NMO), is happy to declare that Dr. Jason Kralic has joined the company in the new role of Vice President of Business Development. Dr. Kralic will be responsible for business development activities, counting partnering, licensing and managing external relationships, and he will report directly to Neil Warma, President and CEO of Opexa.
Opexa Therapeutics, Inc., a biopharmaceutical company, develops personalized immunotherapy to treat multiple sclerosis (MS) and other autoimmune diseases, such as neuromyelitis optica (NMO) based on its proprietary T-cell technology. The company’s product candidate is Tcelna, a novel T-cell immunotherapy, which is in Phase IIb clinical development for the treatment of patients with secondary progressive MS. It is also developing OPX-212 as an autologous T-cell immunotherapy for the treatment of NMO. The company was formerly known as PharmaFrontiers Corp. and changed its name to Opexa Therapeutics, Inc. in June 2006.
At the end of Tuesday’s trade, Veeva Systems Inc (NYSE:VEEV)‘s shares surged 3.66% to $28.33.
Veeva Systems Inc (VEEV) declared a planned partnership to accelerate the life sciences industry’s move to more customer-centric engagement. The companies are joining forces to deliver innovation in customer data and data science for better marketing and sales effectiveness across all channels.
The Veeva and ZS planned partnership will initially focus in two key areas ripe for innovation:
Data Science - ZS has become a Veeva Data Science partner. Powered by data science in ZS’s Suggestion Engine, Veeva CRM Suggestions recommends the best actions and channels to reps to improve sales effectiveness. With this partnership, companies can now leverage ZS’ leading Orchestrator Rep solution to seamlessly deliver recommendations right within Veeva CRM.
Customer Data - ZS has joined the Veeva OpenData Partner Program allowing fast, simple integration of Veeva OpenData healthcare provider, healthcare organization, and affiliations data with ZS’ data solutions.
Veeva Systems Inc. provides cloud-based software solutions for the life sciences industry in North America, Europe, the Asia Pacific, and Latin America. Its solutions comprise Veeva CRM, a customer relationship administration solution that allows pharmaceutical and biotechnology companies to market and sell compliantly to physicians, other healthcare professionals, and healthcare organizations through multiple touch points, counting face-to-face, email, and online; and Veeva Vault, a cloud-based content administration and partnership solution for its customers to manage content-centric processes in various departments within a life sciences company, counting clinical trials, regulatory submissions, quality administration, manufacturing, medical, sales, and marketing.
SYSCO Corporation (NYSE:SYY), ended its Tuesday’s trading session with -0.03% loss, and closed at $37.60.
SYSCO Corporation (SYY) declared that its Board of Directors declared a regular quarterly cash dividend of $0.30 per share, payable on July 24, 2015, to common shareholders of record at the close of business on July 2, 2015.
Sysco Corporation, through its auxiliaries, markets and distributes a range of food and related products primarily to the foodservice or food-away-from-home industry. It operates in Broadline and SYGMA segments. The company distributes a line of frozen foods, such as meats, seafood, fully prepared entrees, fruits, vegetables, and desserts; a line of canned and dry foods; fresh meats; dairy products; beverage products; imported specialties; and fresh produce.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should might occur.
